As previously mentioned, SLITRK6 is a promising candidate for conjugate therapy in bladder cancer [19] and the product of ST6GALNAC1 has been a target in immunotherapy trials for several cancers [23]. Here, ST6GALNAC1 is linked to urinary bladder carcinoma.